Screening for pulmonary arterial hypertension in systemic sclerosis: Now or never!
Zoe R. Brown, Mandana Nikpour

Abstract
Systemic sclerosis (SSc), a chronic multisystem autoimmune disease characterized by fibrosis of the skin and internal organs and vasculopathy, has a high burden of mortality. One of the major contributors to mortality in patients with SSc is pulmonary arterial hypertension (PAH), which affects up to 10% of individuals and results in up to 15 years of life loss. Best practice recommendations are for asymptomatic patients with SSc and SSc-spectrum disorder to be screened annually for the early detection of SSc-PAH. Recently published data from large registries have shown improvements in the long-term outcomes in patients who are diagnosed with SSc-PAH because of systematic annual screening. This review will address the current clinical and research implications of the screening for the early detection of SSc-PAH.

Keywords: Scleroderma, systemic, pulmonary arterial hypertension, mass screening, diagnosis

Introduction
Systemic sclerosis (scleroderma; SSc) is a chronic multisystem autoimmune disease with significant clinical heterogeneity. Three common pathogenetic features include microvascular damage, generalized fibrosis of multiple organs, and dysregulation of innate and adaptive immunity (1).

The prevalence and incidence estimates of SSc vary internationally with higher prevalence reported in Australia, North America, and southern Europe, wherein the estimates range from 154 to 276 cases per million (2). Pulmonary arterial hypertension (PAH) in SSc occurs with an estimated prevalence of 10% and incidence of 1% per annum (3-6). Despite the availability of effective therapies, PAH and other pulmonary complications remain the leading cause of morbidity and mortality in these patients (7, 8).

Recommendations published following the 6th World Symposium on Pulmonary Hypertension (WSPH) in 2018 suggest annual screening of asymptomatic patients with SSc and SSc-spectrum disorders. This has been shown to detect patients with more favorable risk stratification features at diagnosis with PAH and to be associated with improved survival compared to patients diagnosed by routine care (9-12).

Current screening recommendations include various strategies to screen patients, including annual echocardiography. However, echocardiography has limitations as a screening investigation because it relies on the assessment of tricuspid regurgitant (TR) jet velocity to determine the need for further investigation with right heart catheterization (RHC) for the definitive diagnosis of PAH. There is an evidence for discrepancies between the evaluation of TR velocity and right heart parameters by echocardiography compared with RHC, leading to the development of novel multidimensional screening algorithms that use echocardiography as a second-tier screening test (13-15).

Multidimensional screening algorithms using echocardiography as a second-tier investigation, such as the DETECT algorithm and the Australian Scleroderma Interest Group (ASIG) algorithm for the early detection of PAH in patients with SSc, have been developed and evaluated (16, 17). These screening algorithms also incorporate the assessment of known prognostic factors (or risk stratification factors) at the baseline, such as N-terminal probrain natriuretic peptide (NT-proBNP), and are included in the list of recommended screening modalities published following the 6th WSPH (12).

Economic analysis of the screening methods for the detection of PAH in patients with SSc was carried out in French, Australian, and Belgian cohorts, which suggests that screening programs are also cost saving (18, 19).
The DETECT algorithm evaluates the results of 6 nonechocardiographic variables by nomogram to determine a referral for echocardiography in step 1, and in step 2, it determines the need for RHC by evaluating the echocardiographic features (right atrium area and TR velocity) (16). Although initially derived in an enriched cohort of patients with SSc disease duration >3 years and DLCO predicted of ≤60%, the DETECT algorithm has been externally validated in cohorts not meeting these criteria and compared with the 2009 ESC/ERS guidelines. There are 6 studies evaluating the DETECT algorithm in external cohorts, which demonstrate that the algorithm has a comparable performance with the 2009 ESC/ERS guidelines (17, 22-26).

The ASIG algorithm recommends respiratory function tests (RFTs) to evaluate the FVC/DLCO ratio and serum NT-proBNP annually in asymptomatic patients with SSc. If either result is positive, the algorithm advises referral for further evaluation of the presence of PH, including PAH. If the ratio of FVC% predicted to DLCO% predicted is ≥1.8 with DLCO predicted <70%, this suggests a discrepant reduction in the diffusing capacity and is a positive screen. Serum NT-proBNP ≥210 ng/L (or pg/mL) alone is also a positive screen (17). The ASIG algorithm was compared with the DETECT algorithm and the 2009 ESC/ERS guidelines in a cohort of patients with SSc who had been referred for RHC. The ASIG and DETECT algorithms were equally sensitive and were both superior to the 2009 ESC/ERS guidelines. Additionally, the ASIG algorithm outperformed the DETECT algorithm with respect to specificity (54.5% compared to 35.3%) (17).

Despite the published recommendations regarding screening, care gaps remain in practice (27). Analysis of the frequency of annual echocardiograms performed for patients enrolled in the Canadian Scleroderma Research Group after the publication of the 2009 ESC/ERS guidelines revealed that 59.4% of the patients had an echocardiogram after a 1-year follow-up (28). Similarly, a survey of rheumatologists in Australia revealed that only over half of the respondents ordered annual screening for asymptomatic patients with early SSc, and these were even lower for patients with late disease (9).

An independent evaluation of PAH screening practices by rheumatologists in Canada also included evaluation of the frequency of annual screening for dyspnea, as well as annual transthoracic echocardiography (TTE) and RFT. The authors found a discrepancy between the frequency of screening for dyspnea and ordering annual TTE and RFTs (88% of patients compared with 74% and 79%, respectively), suggesting that there are barriers to requesting these tests (29). Concerns have also been
raised regarding the complexity of the composite screening measures, such as the DETECT algorithm, and further evaluation of the feasibility of screening algorithms is an area for future research (30).

Long-term benefits

The most convincing evidence for the long-term benefit of screening for the early detection of SSc-PAH comes from two registries comparing the outcomes between patients whose PAH was detected through routine practice compared with those undergoing systematic annual screening. The results of the Pulmonary Hypertension and Recognition of Outcomes in Scleroderma (PHAROS) registry are also compelling, including a recent publication of the long-term outcomes of patients with SSc who were diagnosed with incident PAH by institutions that actively screen patients for PAH (31).

Humbert et al. (11) compared the outcomes between the patients enrolled in the French PAH Registry and the Itinéraire-Sclérodérmie program. They identified 16 patients whose PAH was diagnosed during scheduled echocardiographic assessment and 16 in whom PAH was diagnosed during routine clinical practice. The detection cohort had significantly higher survival rates of 8 years compared to the routine practice cohort, with 1-, 5-, and 8-year survival of 100%, 73% (95% confidence interval (CI) 43%-89%), and 64% (95% CI 33%-84%), respectively. The 8-year survival in the routine practice cohort was 17% (95% CI 3%-39%) in patients from the same treatment era. The hazard ratio for mortality risk in the routine practice cohort was 4.15 (95% CI 1.47-11.71) (11).

Patients whose PAH was diagnosed because of systematic screening also had better clinical measurements at diagnosis, with a higher proportion of patients meeting the New York Heart Association (NYHA) functional class criteria for class I and II. Patients diagnosed through screening also had better cardiopulmonary hemodynamics at RHC diagnosis of PAH, including lower right atrial pressure (RAP), lower mean pulmonary artery pressure (mPAP), and lower mean pulmonary vascular resistance index (PVR) (11).

These findings are consistent with similar improvements in the long-term outcomes reported in an Australian cohort of patients with SSc undergoing screening. Morrisroe et al. (9) reported the outcomes for patients enrolled in the Australian Scleroderma Cohort Study (ASCS) in which the patients are screened prospectively for the presence of cardiopulmonary complications using annual echocardiography, RFT, and 6-minute walk test (6MWT), if resources permitted. The group compared the outcomes of patients who were diagnosed with PAH at their first visit (who may have had prevalent PAH) with those of the patients who were diagnosed with incident PAH because of subsequent annual screening and found that 3-year survival was significantly better in the group diagnosed with PAH through subsequent screening. Furthermore, 3-year survival in the screened cohort from the time of PAH diagnosis was 94.7% compared to 42.7% (p<0.001) in the population diagnosed at the first visit (9).

Similarly, screening detected the patients with more favorable hemodynamic and prognostic characteristics at baseline, including significantly lower mean PVR, lower mPAP, and higher mean 6-minute walk distance (6MWD). Patients diagnosed with PAH on subsequent screens compared to the first screen were also more likely to be in a better World Health Organization functional class (9).
Brown and Nikpour. Screening for PAH in systemic sclerosis

The ASIG Algorithm

- **Annual Respiratory Function Test (RFT) & Serum NT-proBNP Level**
- **Negative Screen**
  - NT-proBNP < 210 pg/mL
  - DLCO ≥ 70% with FVC / DLCO < 1.8
  - Repeat in 12 months
- **Positive Screen**
  - NT-proBNP ≥ 210 pg/mL
  - OR
  - DLCO ≤ 70% with FVC / DLCO ≥ 1.8
  - Referral for further assessment of PAH (TTE, RHC)

**Figure 3.** The Australian Scleroderma Interest Group (ASIG) algorithm.*

*The ASIG algorithm evaluates annual serum N-terminal pro-brain natriuretic peptide (NT-proBNP) level and FVC/ DLCO ratio to determine the need for further assessment of pulmonary hypertension (PH) (21).

FVC: forced vital capacity % predicted; DLCO: diffusion capacity of the lung for carbon monoxide corrected % predicted.

**Dictated; TTE: transthoracic echocardiography; RHC: right heart catheterization.**

rates, when events were restricted to PAH-related deaths, at 1, 3, and 5 years after diagnosis were 97%, 83%, and 76%, respectively (31). The Ghent University SSc cohort also demonstrated lower mPAP at diagnosis of PAH after the implementation of screening in 2009 (32).

**Cost savings**

Available data suggest that screening programs for the systematic detection of PAH in patients with SSc can be cost saving. Analysis of the investigations performed during the ItinérAIR-Sclérodémie program revealed that 31 echocardiograms and 1.8 RHC were performed for each diagnosis of PAH with an estimated cost of £2,675 per diagnosis (11).

The average cost per patient attending the Ghent University Hospital SSc unit per PAH screening between February 2015 and February 2016 was estimated as EUR80 for annual echocardiography according to the 2009 ESC/ ERS guidelines compared to EUR224 per patient screened using the DETECT algorithm. In the cohorts screened prior to the implementation of the DETECT algorithm, the average cost of screening per patient was EUR112 (26).

**Cost analysis of the ASIG algorithm** (annual RFT and serum NT-proBNP) is performed by evaluating the cost of the ASIG algorithm compared to the screening with annual RFT and echocardiography. The NT-proBNP-based algorithm resulted in a cost saving of 14% per case of PAH diagnosed (19).

**True cost-effectiveness analyses**, incorporating the survival data and health-related quality of life data, are needed to definitively quantify the cost-effectiveness of the screening programs for SSc-PAH.

**Research implications**

**Frequency of detection of “borderline PAH”**

Following the 6th WSPH, an updated definition of precapillary PH was published. According to a scientific approach, precapillary PH is best defined by mPAP >20 mm Hg, pulmonary arterial wedge pressure ≤15 mm Hg, and PVR ≥3 Woods Units (33).

Vandecasteele et al. (26) addressed this in an analysis of 195 consecutive SSC patients screened using different algorithms. Borderline PH was defined as mPAP of 21-24 mm Hg during RHC. According to the DETECT algorithm, 13 of 14 patients (93%) with borderline PH were referred for diagnostic RHC, and according to the 2015 ESC/ERS guidelines, 10 of 14 patients with borderline PH (71%) were referred for RHC by screening with annual echocardiography (26).

Hoffmann-Vold et al. (34) likewise evaluated the incidence of borderline PH in an unselected cohort of 161 SSc patients attending the Oslo University Hospital before and after the implementation of the DETECT algorithm. Before the implementation of the DETECT algorithm, the patients were screened annually by complete clinical examination, echocardiogram, RFT, 6MWT, and NT-proBNP. They found no significant differences in the hemodynamic parameters at incident RHC between the cohort screened before the implementation of the DETECT algorithm and those screened by the DETECT algorithm. In the DETECT cohort, 26 patients (31%) were diagnosed with borderline PH compared with 13 patients (16.9%) in the cohort screened prior to the implementation of the DETECT algorithm (34).

A screening algorithm that incorporates risk stratification at baseline

**Over the last 15 years, the therapeutic approach for the management of patients with PAH has evolved with the evidence for improved outcomes in the setting of selection of therapy based on multidimensional risk stratification of the severity of newly diagnosed PAH.** Subsequent escalation of therapy, in a “treat-to-target” fashion, is based on the systematic evaluation of clinical response and maintenance or attainment of a low-risk status at follow-up. This in turn correlates with a much better long-term survival (35-37).

**Cost savings**

Available data suggest that screening programs for the systematic detection of PAH in patients with SSc can be cost saving. Analysis of the investigations performed during the ItinérAIR-Sclérodémie program revealed that 31 echocardiograms and 1.8 RHC were performed for each diagnosis of PAH with an estimated cost of £2,675 per diagnosis (11).

The average cost per patient attending the Ghent University Hospital SSc unit per PAH screening between February 2015 and February 2016 was estimated as EUR80 for annual echocardiography according to the 2009 ESC/ ERS guidelines compared to EUR224 per patient screened using the DETECT algorithm. In the cohorts screened prior to the implementation of the DETECT algorithm, the average cost of screening per patient was EUR112 (26).

**Cost analysis of the ASIG algorithm** (annual RFT and serum NT-proBNP) is performed by evaluating the cost of the ASIG algorithm compared to the screening with annual RFT and echocardiography. The NT-proBNP-based algorithm resulted in a cost saving of 14% per case of PAH diagnosed (19).

**True cost-effectiveness analyses**, incorporating the survival data and health-related quality of life data, are needed to definitively quantify the cost-effectiveness of the screening programs for SSc-PAH.

**Research implications**

**Frequency of detection of “borderline PAH”**

Following the 6th WSPH, an updated definition of precapillary PH was published. According to a scientific approach, precapillary PH is best defined by mPAP >20 mm Hg, pulmonary arterial wedge pressure ≤15 mm Hg, and PVR ≥3 Woods Units (33).

Vandecasteele et al. (26) addressed this in an analysis of 195 consecutive SSC patients screened using different algorithms. Borderline PH was defined as mPAP of 21-24 mm Hg during RHC. According to the DETECT algorithm, 13 of 14 patients (93%) with borderline PH were referred for diagnostic RHC, and according to the 2015 ESC/ERS guidelines, 10 of 14 patients with borderline PH (71%) were referred for RHC by screening with annual echocardiography (26).

Hoffmann-Vold et al. (34) likewise evaluated the incidence of borderline PH in an unselected cohort of 161 SSc patients attending the Oslo University Hospital before and after the implementation of the DETECT algorithm. Before the implementation of the DETECT algorithm, the patients were screened annually by complete clinical examination, echocardiogram, RFT, 6MWT, and NT-proBNP. They found no significant differences in the hemodynamic parameters at incident RHC between the cohort screened before the implementation of the DETECT algorithm and those screened by the DETECT algorithm. In the DETECT cohort, 26 patients (31%) were diagnosed with borderline PH compared with 13 patients (16.9%) in the cohort screened prior to the implementation of the DETECT algorithm (34).

A screening algorithm that incorporates risk stratification at baseline

**Over the last 15 years, the therapeutic approach for the management of patients with PAH has evolved with the evidence for improved outcomes in the setting of selection of therapy based on multidimensional risk stratification of the severity of newly diagnosed PAH.** Subsequent escalation of therapy, in a “treat-to-target” fashion, is based on the systematic evaluation of clinical response and maintenance or attainment of a low-risk status at follow-up. This in turn correlates with a much better long-term survival (35-37).

There exist several baseline and follow-up risk stratification calculators. The most frequently evaluated risk stratification tools are the Registry to Evaluate Early and Long-term PAH Disease Management risk score calculator and the risk table from the 2015 ESC/ERS PH guidelines (35).

**Risk stratification is similar between the proposed calculators and includes the assessment of clinical characteristics, including the functional class, 6MWD, biochemical results, particularly NT-proBNP or BNP, and RHC hemodynamic parameters, such as RAP and mixed venous oxygen saturation (35). Therefore, a screening algorithm that incorporates the baseline evaluation of prognostic factors may contribute to a more streamlined evaluation and therapeutic strategy.**

**Conclusion**

International registries of patients with SSC-PAH undergoing systematic screening for the
early detection of SSc-PAH have reported improvements in the survival with more patients being diagnosed in a low-risk status at the baseline. Best practice care of SSc should incorporate a screening program that facilitates a multidimensional PAH risk evaluation at the baseline and institution of early intervention with systematic clinical review of response to therapy guiding the therapeutic decisions.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - Z.R.B., M.N.; Design - Z.R.B., M.N.; Supervision - Z.R.B., M.N.; Data Collection and/or Processing - Z.R.B., M.N.; Analysis and/or Interpretation - Z.R.B., M.N.; Literature Search - Z.R.B., M.N.; Writing Manuscript - Z.R.B., M.N.; Critical Review - Z.R.B., M.N.

**Conflict of Interest:** Z.R.B. is supported by the research funding support from the Australian Commonwealth Government through the University of Melbourne Research Training Program Scholarship. M.N. is supported by grant from the Actelion.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**References**

1. Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nat Rev Dis Primers 2015; 1: 15002. [Crossref]
2. Chiffont H, Faurel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: A systematic literature review. Semin Arthritis Rheum 2008; 37: 223-35. [Crossref]
3. Morrisroe K, Huq M, Stevens W, Rabasa C, Proudman SM, Nikpour M. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: Results from a large multicenter cohort study. BMC Pulm Med 2016; 16: 134. [Crossref]
4. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831-9. [Crossref]
5. Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: Different phenotypes. Eur Respir Rev 2017; 26: 170056 J. [Crossref]
6. Giordano N, Corallo C, Chirico C, Bazzi A, Marinetti A, Foravanti A, et al. Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines. J Scleroderma Relat Disord 2018; 4: 35-42. [Crossref]
7. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010; 9: A311-8. [Crossref]
8. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4. [Crossref]
9. Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: Results from a real-life screening programme. Arthritis Res Ther 2017; 19: 122. [Crossref]
10. Galili N, Humbert M, Vachery JL, Gibbs S, Lang I, Torbicki A, et al. [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. Kardiol Pol 2015; 73: 1127-206. [Crossref]
11. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-30. [Crossref]
12. Frost A, Badesch D, Gibbs JSR, Gropalan D, Khan na D, Manes A, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2019; 53: 1801904. [Crossref]
13. O’Leary JM, Assad TR, Xu M, Farber-Eger E, Wells QS, Hennes AR, et al. Lack of a tricuspid regurgitation Doppler signal and pulmonary hypertension by invasive measurement. J Am Heart Assoc 2018; 7: e009362. [Crossref]
14. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615-21. [Crossref]
15. Baran M. Pros and cons of echocardiography in the screening, diagnosis and follow-up of patients with systemic sclerosis pulmonary arterial hypertension - A rheumatologist’s perspective. J Scleroderma Relat Disord 2017; 2: 108-14. [Crossref]
16. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study. Ann Rheum Dis 2014; 73: 1340-9. [Crossref]
17. Hao Y, Thakkovar K, Stevens W, Morrisroe K, Prior D, Rabasa C, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Respir Res Ther 2015; 17: 7. [Crossref]
18. Vachyiri J-L, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18: 162-9. [Crossref]
19. Quinlivan A, Thakkor V, Stevens W, Morrisroe K, Prior D, Rabasa C, et al. Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis. Intern Med J 2015; 45: 1134-40. [Crossref]
20. Young A, Nagaraja V, Basilious M, Habbib M, Townsend W, Gladue H, et al. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Semin Arthritis Rheum 2019; 48: 1059-67. [Crossref]
21. Thakkor V, Stevens W, Prior D, Yousef P, Liew D, Gabbay E, et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: A cohort study. Arthritis Res Ther 2013; 15: R193. [Crossref]
22. Koutsianas C, Subasinghe S, Douglas K. FR0382 use of the detect algorithm for early pulmonary artery hypertension diagnosis in patients with systemic sclerosis in everyday clinical practice. Ann Rheum Dis 2017; 76(Suppl 2): 632. [Crossref]
23. Ancuta C, Pomriealu C, Maxim R, Mitu F. FR0383 detect screening for pulmonary arteri al hypertension in systemic sclerosis: Data from an eustar cohort. Ann Rheum Dis 2017; 76(Suppl 2): 632-3. [Crossref]
24. Corrier V, Lescoat A, Fournet M, Cazaletes C, Coiffier G, Joueneau S, et al. [Screening for pul monary arterial hypertension in patients with systemic sclerosis: Comparison of DETECT algo rithm to decisions of a multidisciplinary team, in a competence centre]. Rev Med Interne 2017; 38: 502-7. [Crossref]
25. Hoffmann-Vold AM, Fretheim H, Midvedt O, Kilian K, Angelshaug M, Chaudhary A, et al. Frequ encies of borderline pulmonary hypertension before and after the DETECT algorithm: Results from a prospective systemic sclerosis cohort. Rheumatology 2018; 57: 480-7. [Crossref]
26. Vandecasteele E, Drieghe B, Melissen K, Thevis sen K, De Pauw M, Deschepper E, et al. Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. Eur Respir J 2017; 49: 1602275. [Crossref]
27. Pope JE. Pulmonary arterial hypertension in sclerodema: Care gaps in screening. Arthritis Res Ther 2017; 19: 128. [Crossref]
28. Pope J, Harding S, Khindas S, Bonner A. Agreement with guidelines from a large database for management of systemic sclerosis: Results from the Canadian Scleroderma Research Group. J Rheumatol 2012; 39: 524-31.
29. Kelly D, Beattie KA, Larché MJ. Pulmonary arteri al hypertension screening of systemic sclerosis patients in clinical practice: An independent chart review. J Scleroderma Relat Disord 2017; 2: 231-4. [Crossref]
30. Morsley K, Williamson L. Screening for pulmonary hypertension in scleroderma. J Scleroderma Relat Disord 2017; 2: e5-e. [Crossref]
31. Kolstad KD, Li S, Steen V, Chung L. Long-term outcomes in systemic sclerosis-associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest 2018; 154: 862-71. [Crossref]
32. Vandecasteele E, Melissen K, Thevissen K, De Pauw M, Deschepper E, Decuman S, et al. Preva lence and incidence of pulmonary arterial hyper tension: 10-year follow-up of an unselected systemic sclerosis cohort. J Scleroderma Relat Disord 2017; 2: 196-202. [Crossref]
33. Simonneau G, Montani D, Celerier DS, Dent on CP, Gatzaoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. [Crossref]
34. Hoffmann-Vold A-M, Fretheim H, Midvedt O, Kilian K, Angelshaug M, Chaudhary A, et al. Frequ encies of borderline pulmonary hypertension before and after the DETECT algorithm: Results from a prospective systemic sclerosis cohort. Rheumatology 2017; 57: 480-7. [Crossref]
35. Galié N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801913. [Crossref]

36. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589-96. [Crossref]

37. Benza RL, Miller DP, Foreman AJ, Frost AE, Badesch DB, Benton WW, et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant 2015; 34: 356-61. [Crossref]